A Phase Ib study of ruxolitinib combined with afatinib, an inhibitor of mutant EGFR, in patients with NSCLC showed that this regimen was both well-tolerated and displayed activity against this malignancy, as 23.3% displayed a partial response and 80% had stable disease (NCT02145637)[96]. Here, EGFR is linked to non-small cell lung carcinoma.